Tivey, A., Shotton, R., Eyre, T. A., Lewis, D., Crosbie, N., Nga, E., Guerrero Camacho, R., Swe, W., Marr, H., Rees, C., Moule, S., Sutton, T., Wrench, D., Thomas, N., Wilson, M., Bailey, J., Prahladan, M., Hodson, A., Koppana, M., Smith, S., Jones, S., Miall, F., Norman, J., Davies, E., Hildyard, C., Lowry, L., Paneesha, S., Qureshi, I., Beech, A., Bedford, C., Everden, A., Tucker, D., Wright, J., Goddard, J., Nicholson, T., Wilson, J., Lord, A., Jackson, B., Flont, M., Gibb, A., & Linton, K. (n.d.). p1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY. HemaSphere, 6, 1031–1032. http://access.bl.uk/ark:/81055/vdc_100159757456.0x000001